Regulatory advisors appointed for BZDS1901
Filed with ASX · · 4 pages · English
Summary by 6ix AI
This early engagement aims to enhance the efficiency of clinical trial preparations and explore expedited regulatory pathways for the therapy. The collaboration with Dark Horse Consulting is expected to align AdAlta's clinical and manufacturing strategies with FDA expectations before formal submissions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- $2.5m placement
- BZDS1901 manufacturing agreement
- Automated cell therapy manufacturing MoU
- BZDS1901 clinical update
- AdCella and SHcell hold first JDC meeting
Later from AdAlta
- Second BZDS1901 milestone paid
- Oktopi AI collaboration for research efficiency
- 2 year survival milestone for EW-001 patient
- EW-001 IIT study overall survival update
- BZDS1901 special access scheme launch in China
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta